Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.67 |
| ▸ | F11 | P03951 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 2/20 | 0.60 |
| ▸ | CA2 | P00918 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.60 |
| ▸ | PDE5A | O76074 | 1/20 | 0.60 |
| ▸ | HMGCR | P04035 | 1/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CA6 | P23280 | 1/20 | 0.60 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.60 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.60 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.60 |
| ▸ | TST | Q16762 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7642894 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL18083458 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL7144957 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL7251000 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL12326369 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL3785587 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL18068260 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL16731442 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL7642890 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 | |
| SCHEMBL17633988 | 1.00 | PTPN1 (0.67) | PTPN1F11USP2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | PTPN1 4743/4885F11 1310/4885USP2 3744/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | PTPN1 4669/4885F11 1013/4885USP2 3465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.